Proof of Concept: A PhRMA Position Paper With Recommendations for Best Practice
暂无分享,去创建一个
S Madani | S. Cohen | J. Fleishaker | S A Williams | S. Williams | S Cohen | M E Cartwright | J. McLeod | J C Fleishaker | J F McLeod | B Musser | M. Cartwright | B. Musser | S. Madani
[1] J. Wagner. Strategic approach to fit-for-purpose biomarkers in drug development. , 2008, Annual review of pharmacology and toxicology.
[2] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[3] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[4] P. Sandercock,et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review , 2006, BMJ : British Medical Journal.
[5] J. DiMasi. The Value of Improving the Productivity of the Drug Development Process , 2012, PharmacoEconomics.
[6] M. Milad,et al. Model-based development of gemcabene, a new lipid-altering agent , 2005, The AAPS Journal.
[7] Paul F. Reynolds,et al. The Role of Modeling and Simulation , 2008 .
[8] R. Frank,et al. New estimates of drug development costs. , 2003, Journal of health economics.
[9] Vikram Sinha,et al. Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation , 2005, The AAPS Journal.
[10] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[11] L B Sheiner,et al. Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.
[12] N H Holford,et al. Simulation of clinical trials. , 2000, Annual review of pharmacology and toxicology.
[13] Bruce H. Littman,et al. The ultimate model organism: progress in experimental medicine , 2005, Nature Reviews Drug Discovery.
[14] M. Heinrich,et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] Stephen A. Williams,et al. The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development , 2009, Clinical pharmacology and therapeutics.
[16] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.